Using CSF Biomarkers for Differential Diagnosis of Neurological Diseases
Drug development for neurodegenerative brain diseases such as Parkinson’s or dementia, of which Alzheimer’s is the most common form, needs to focus on patients early in the disease, not those where brain damage has already occurred.
Diagnosing and treating patients more effectively earlier will, even if you aren’t able to instigate a cure, offer the ability to modify the disease progression and slow or delay when brain damage occurs. In the case of Alzheimer’s, once the amyloid plaques (tangles of misshapen proteins) have accumulated in nervous tissue, it has so far been impossible to untangle or remove them.
As a European snow bird she would travel to Malta each year to escape the damp, grey English winters. One year when I visited her in Malta, I noticed when she went up to the hotel dinner buffet, she could not “remember” where to return to.
